U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Capreomycin is an antibiotic, which is used in combination other antituberculosis drugs fro the treatment of pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins.

CNS Activity

Approval Year

1971
86
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
CAPASTAT SULFATE

Approved Use

Capastat Sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis.

Launch Date

4.4668801E10
PubMed

PubMed

TitleDatePubMed
Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
2005 Aug
Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs.
2006 Jul 21
Capreomycin--a polypeptide antitubercular antibiotic with unusual binding properties toward copper(II).
2012 Jan
Patents

Patents

EP0065884
2
EP0173990
2
EP0315300
2
EP0475160
2
EP0786999
2

Sample Use Guides

In Vivo Use Guide
Intravenously: Capastat Sulfate (Capreomycin for Injection) should be diluted in 100 mL of 0.9% Sodium Chloride Injection and administered over 60 minutes. Intramuscularly — Reconstituted Capastat Sulfate should be given by deep intramuscular injection into a large muscle mass, since superficial injection may be associated with increased pain and the development of sterile abscesses. For administration of a 1-g dose, the entire contents of the vial should be given. For doses lower than 1 g, the following dilution table may be used.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Mixture
Created
by admin
on Fri Dec 15 15:41:08 UTC 2023
Edited
by admin
on Fri Dec 15 15:41:08 UTC 2023
Record UNII
232HYX66HC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAPREOMYCIN
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CAPREOMYCIN [HSDB]
Common Name English
CAPREOMICIN
Common Name English
Capreomycin [WHO-DD]
Common Name English
CAPREOMYCIN [MI]
Common Name English
CAPOSTATIN
Common Name English
capreomycin [INN]
Common Name English
CAPASTAT
Brand Name English
CAPREOMYCIN [VANDF]
Common Name English
CAPROMYCIN
Common Name English
Classification Tree Code System Code
WHO-VATC QJ04AB30
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
NDF-RT N0000175483
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
NCI_THESAURUS C280
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
LIVERTOX NBK548641
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
NCI_THESAURUS C2363
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
WHO-ATC J04AB30
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
Code System Code Type Description
MERCK INDEX
m3029
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2221250
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
RXCUI
78903
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY RxNorm
EVMPD
SUB01028MIG
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
DRUG BANK
DB00314
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
HSDB
3211
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
WIKIPEDIA
CAPREOMYCIN
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
DRUG CENTRAL
3063
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID8040989
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
INN
1145
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
NCI_THESAURUS
C72607
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
MESH
D002207
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
LACTMED
Capreomycin
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
CAS
11003-38-6
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
FDA UNII
232HYX66HC
Created by admin on Fri Dec 15 15:41:08 UTC 2023 , Edited by admin on Fri Dec 15 15:41:08 UTC 2023
PRIMARY
All of the following components must be present:
Structure of CAPREOMYCIN IB
Structure of CAPREOMYCIN IIA
Structure of CAPREOMYCIN IA
Structure of CAPREOMYCIN IIB
Related Record Type Details
CAPREOMYCIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Definition References
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966